Analyst Expectations for Revance Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) has received 5 bullish analyst ratings in the last quarter, with an average price target of $41.8, implying an upside from the current price of $32.115. The average price target has increased by 9.05% from the previous average of $38.33.
June 07, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics has 5 bullish analyst ratings with an average price target of $41.8, indicating a potential upside from the current price of $32.115.
The article mentions that Revance Therapeutics has received 5 bullish analyst ratings in the last quarter, with an average price target of $41.8, which is higher than the current price of $32.115. This indicates a potential upside for the stock in the short term. The average price target has also increased by 9.05% from the previous average, which further supports the bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100